Aurobindo Pharma gains as its arm completes acquisition of Lannett Company
Aurobindo Pharma is currently trading at Rs. 1564.00, up by 15.15 points or 0.98% from its previous closing of Rs. 1548.85 on the BSE.
The scrip opened at Rs. 1548.90 and has touched a high and low of Rs. 1578.50 and Rs. 1548.90 respectively. So far 31637 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1585.55 on 29-Jun-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1585.55 and Rs. 1,527.10 respectively. The current market cap of the company is Rs. 90043.76 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.11% and 7.08% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., (APUSA) has successfully completed its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on June 18, 2026. Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition. By combining capabilities and resources, the organization aims to enhance the availability of essential medicines and deliver sustained, long-term value to patients, customers, and stakeholders.
